相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
Lucia Echevarria et al.
NUCLEIC ACID THERAPEUTICS (2019)
Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene
Yusuke Echigoya et al.
MOLECULAR THERAPY (2019)
Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study
Niels Hilhorst et al.
EUROPEAN JOURNAL OF PEDIATRICS (2019)
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
Alison M. Blain et al.
PLOS ONE (2018)
Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
Hirofumi Komaki et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
Naoki Watanabe et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy
Yusuke Echigoya et al.
MOLECULAR THERAPY (2017)
Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan
Mariko Okubo et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy
Yusuke Echigoya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Eteplirsen in the treatment of Duchenne muscular dystrophy
Kenji Rowel Q. Lim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
Quynh Nguyen et al.
JOURNAL OF PERSONALIZED MEDICINE (2017)
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2016)
Approving a Problematic Muscular Dystrophy Drug Implications for FDA Policy
Aaron S. Kesselheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation
Radulfus WN Slijkerman et al.
Molecular Therapy-Nucleic Acids (2016)
Exon skipping therapy for Duchenne muscular dystrophy
Ryszard Kole et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
Ashley Guncay et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Aurelie Goyenvalle et al.
NATURE MEDICINE (2015)
Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45-55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
Yusuke Echigoya et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy
Yusuke Echigoya et al.
PLOS ONE (2015)
DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations
Jonas Juan-Mateu et al.
PLOS ONE (2015)
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Dana Maria Copolovici et al.
ACS NANO (2014)
Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro
Takenori Shimo et al.
NUCLEIC ACIDS RESEARCH (2014)
Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
Kavitha Siva et al.
NUCLEIC ACID THERAPEUTICS (2014)
Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Stuart J. Moat et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
Long-Term Rescue of Dystrophin Expression and Improvement in Muscle Pathology and Function in Dystrophic mdx Mice by Peptide-Conjugated Morpholino
Bo Wu et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
Toshifumi Yokota et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Antisense-based therapy for the treatment of spinal muscular atrophy
Frank Rigo et al.
JOURNAL OF CELL BIOLOGY (2012)
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery
Yoshitsugu Aoki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
Akinori Nakamura et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Antisense-induced Myostatin Exon Skipping Leads to Muscle Hypertrophy in Mice Following Octa-guanidine Morpholino Oligomer Treatment
Jagjeet K. Kang et al.
MOLECULAR THERAPY (2011)
Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders
Kamel Mamchaoui et al.
SKELETAL MUSCLE (2011)
RNA-targeted splice-correction therapy for neuromuscular disease
Matthew J. A. Wood et al.
BRAIN (2010)
Therapeutic exon skipping for dysferlinopathies?
Annemieke Aartsma-Rus et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
Hans Heemskerk et al.
MOLECULAR THERAPY (2010)
In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse
Yoshitsugu Aoki et al.
MOLECULAR THERAPY (2010)
Efficacy of Systemic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs
Toshifumi Yokota et al.
ANNALS OF NEUROLOGY (2009)
A Renaissance for Antisense Oligonucleotide Drugs in Neurology
Toshifumi Yokota et al.
ARCHIVES OF NEUROLOGY (2009)
Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort
Kevin M. Flanigan et al.
HUMAN MUTATION (2009)
Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
Annemieke Aartsma-Rus et al.
MOLECULAR THERAPY (2009)
Octa-guanidine Morpholino Restores Dystrophin Expression in Cardiac and Skeletal Muscles and Ameliorates Pathology in Dystrophic mdx Mice
Bo Wu et al.
MOLECULAR THERAPY (2009)
Design of Phosphorodiamidate Morpholino Oligomers ( PMOs) for the Induction of Exon Skipping of the Human DMD Gene
Linda J. Popplewell et al.
MOLECULAR THERAPY (2009)
Exon-skipping therapy for Duchenne muscular dystrophy
Akinori Nakamura et al.
NEUROPATHOLOGY (2009)
Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo
Yong-Fu Li et al.
BIOCONJUGATE CHEMISTRY (2008)
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript
Steve D. Wilton et al.
MOLECULAR THERAPY (2007)
The influence of antisense oligonucleotide length on dystrophin exon skipping
P. L. Harding et al.
MOLECULAR THERAPY (2007)
Morpholino, siRNA, and S-DNA compared: Impact of structure and mechanism of action on off-target effects and sequence specificity
James E. Summerton
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
J Alter et al.
NATURE MEDICINE (2006)
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
A Amantana et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Delivery of bioactive molecules into the cell:: The Trojan horse approach
GPH Dietz et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2004)
Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle
BL Gebski et al.
HUMAN MOLECULAR GENETICS (2003)
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
A Aartsma-Rus et al.
HUMAN MOLECULAR GENETICS (2003)
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
F Muntoni et al.
LANCET NEUROLOGY (2003)
Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy
CJ Mann et al.
JOURNAL OF GENE MEDICINE (2002)
Deflazacort treatment of Duchenne muscular dystrophy
WD Biggar et al.
JOURNAL OF PEDIATRICS (2001)
分享论文
